Literature DB >> 16179010

Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization.

A C Wallgren1, B Andersson, A Bäcker, A Karlsson-Parra.   

Abstract

T-cell sensitization to indirectly presented alloantigens (indirect pathway of allorecognition) plays a critical role in chronic rejection. The usual very efficient priming of such self-restricted, T helper type 1 (Th1)-deviated CD4+ T cells obviously conflicts with the fact that allogeneic MHC molecules are poorly immunogenic per se. The aim of the present study is to elucidate whether direct allosensitization induces production of inflammatory mediators that may affect recruitment and activation of immature bystander (host) dendritic cells (DC). These potential mechanisms were studied in vitro by conducting primary allogeneic mixed leucocyte reactions (MLR), mimicking the priming phase in secondary lymphoid organs, and secondary MLR, mimicking the effector phase within the graft. Primary, and particularly secondary, MLR supernatants were found to contain high levels of monocyte/immature DC-recruiting CC chemokines and pro-inflammatory cytokines. Exposure of immature DC to primary or secondary MLR supernatants was found to upregulate CD40 expression and further enhanced lipopolysaccharide-induced interleukin-12 (IL-12) p70 production. Secondary MLR supernatants additionally induced upregulation of CD86 and deviated allogeneic T-cell responses towards Th1 (enhanced interferon-gamma production without concomitant induction of detectable IL-4 or IL-10 production). These findings indicate that direct allorecognition may act as a Th1-deviating adjuvant for indirect allosensitization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179010     DOI: 10.1111/j.1365-3083.2005.01663.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathy.

Authors:  Yu-Mee Wee; Joo-Hee Jung; Yang-Hee Kim; Monica-Y Choi; Young-Hoon Kim; Do-Sook Choi; Myung-Hwan Cho; Duck-Jong Han
Journal:  Exp Biol Med (Maywood)       Date:  2015-09-07

2.  Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Authors:  Grammatiki Fotaki; Chuan Jin; Mohanraj Ramachandran; Iliana Kyriaki Kerzeli; Alex Karlsson-Parra; Di Yu; Magnus Essand
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

3.  Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Authors:  Anna Laurell; Maria Lönnemark; Einar Brekkan; Anders Magnusson; Anna Tolf; Anna Carin Wallgren; Bengt Andersson; Lars Adamson; Rolf Kiessling; Alex Karlsson-Parra
Journal:  J Immunother Cancer       Date:  2017-06-20       Impact factor: 13.751

4.  Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma.

Authors:  Magnus Rizell; Malin Sternby Eilard; Mats Andersson; Bengt Andersson; Alex Karlsson-Parra; Peter Suenaert
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

Review 5.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

6.  Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.

Authors:  Grammatiki Fotaki; Chuan Jin; Iliana Kyriaki Kerzeli; Mohanraj Ramachandran; Minttu-Maria Martikainen; Alex Karlsson-Parra; Di Yu; Magnus Essand
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

7.  Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.

Authors:  Alex Karlsson-Parra; Juliana Kovacka; Emilia Heimann; Margareth Jorvid; Sijme Zeilemaker; Sharon Longhurst; Peter Suenaert
Journal:  Pharm Res       Date:  2018-06-14       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.